Abstract
Reports of unusual microorganisms causing human infections are on the rise in the recent years due to transition in epidemiological trends. Commensal/normal flora which are otherwise termed as “good bacteria” are now causing infections in different group of patients, mostly immunocompromised. Various host and environmental factors play a pivotal role in microbial transmigration from their normal habitat into blood and other body sites. We report one such “good bacteria” associated with sepsis in a patient who was given the same bacterium in the form of probiotics.
Introduction
Probiotics are live microorganisms which have the ability to colonize human gut and exert beneficial effects.1 Organisms commonly used as probiotics are Lactobacilli, Bifidobacterium, Bacillus sp., Enterococci, Escherichia, Streptococcus or fungi such as Saccharomyces boulardi.2,3 The beneficial effects of probiotics documented in literature are: synthesis of vitamins, prevent colonization of pathogenic bacteria, antagonize other bacteria by secreting bacteriocins and other antibacterial substances, stimulation of secretory IgA antibodies which antagonize other pathogens, etc.3 These benefits make them a potential option in treating antibiotic associated colitis, critically ill and surgical patients, diarrhea in children as well as adults. Although the beneficial effects of probiotics are well publicized, the risk and drawbacks due to the same is almost always neglected. There have been reports of various probiotic bacteria such as Bacillus subtilis causing sepsis but very few reports from India and Philippines have surfaced in the recent months on Bacillus clausii sepsis in immunocompromised individuals and in neonates. We encountered a diabetic adult but an otherwise normal individual developing sepsis with B. clausii, the source of which was traced to be the same organism given to her in the form of probiotics. To the best of our knowledge, this is the first report of Bacillus clausii causing sepsis in an immunocompetent adult.
Case description
Our patient is a 45-year-old diabetic, not a known hypertensive, no history of any other chronic illness and no other significant past or family history. She presented to the emergency department with acute onset frontal headache of one day duration. She was diagnosed with cerebral vein thrombosis with right parietal intraparenchymal bleeding with edema and midline shift. Emergency decompressive craniotomy was done for her. She was gradually weaned off the ventilator and tracheostomy tube were decannulated. She was mobilized and her GCS improved to 15/15. After 26 days she underwent autologous and mesh cranioplasty. She then developed subgaleal hematoma 7 days after the cranioplasty for which she underwent re-exploration and evacuation of hematoma. She again developed recurrent subgaleal and extradural hematoma with midline shift and drop in GCS to 5/15. She underwent emergency re-exploration and evacuation of hematoma with bone flap removal with significant blood loss which was corrected with transfusion of 6 units blood and blood products. She was being continuously monitored in the neurosurgical intensive care unit and treated with appropriate line of medication after four surgical procedures. On the third postoperative day of the last surgery her tracheal secretion grew Klebsiella pneumoniae which was multidrug resistant. Drain fluid and pus taken from the surgical site also grew multidrug resistant Klebsiella pneumoniae. She was treated with appropriate antibiotics and with the probiotic Enterogermina (Bacillus clausii spores suspension 2 billion/5 mL, strains: O/C, N/R, SIN and T)5 as she developed loose stools on broad spectrum antibiotics. After about ten days she developed fever after which two sets of blood cultures were drawn from two different sites. An elevated procalcitonin level of >0.5 to ≤2 ng/mL was noted. Two aerobic blood culture bottles grew Gram positive bacilli within 48 hours which was isolated in pure culture and identified as Bacillus clausii by Matrix Assisted Laser Desorption Ionization Time of Flight Assay (MALDI-TOF; Biomeriéux, France). Growth was observed eleven days after initiation of the probiotic containing spores of Bacillus clausii. Phenotypic drug susceptibility testing for minimum inhibitory concentration (MIC) using E test was performed using Clinical Laboratory Standards Institute (CLSI) M45 guidelines.4 The isolate was susceptible to ciprofloxacin (MIC value: 0.38 µg/mL) and vancomycin (MIC value: 0.5 µg/mL) but resistant to penicillin (MIC value: 32 µg/mL). All other recommended antibiotics were tested using Kirby Bauer disk diffusion but not reported since there are no interpretative guidelines by CLSI. In order to correlate the origin of blood isolate, the probiotic was subjected to identification following aerobic culture. We were able to isolate and identify the organism as Bacillus clausii using MALDI TOF with susceptibility pattern of the probiotic strain perfectly matching the blood isolate. These phenotypically correlative findings convinced us to establish the probable source of B. clausii in blood to be from the probiotic. Patient was treated with teicoplanin which showed an MIC of 0.094 µg/mL, however it could not be reported as susceptible due to unavailability of interpretative guidelines. Patient responded well to antibiotic therapy and became afebrile with very good resolution of sepsis within 48 hours of teicoplanin initiation. Repeat blood cultures drawn after two weeks of initial blood cultures showed no growth, thereby signifying adequate response to antibiotic therapy.
Discussion
The usefulness and disadvantages of using Bacillus clausii spores as probiotics in critically ill patients is discussed hereunder. It is noteworthy that B. clausii in our patient is definitely a rare occurrence compared to previous reports of B. clausii sepsis. Our patient did not have any underlying immunocompromising condition such as malignancy, corticosteroid therapy, transplantation, immunodeficiency syndromes, etc. This observation is contrary to previously published reports of B. clausii associated with sepsis in individuals with either one of the above listed immunocompromising conditions.6,7 Therefore it is noteworthy that B. clausii used as probiotics can transmigrate the gut and enter the bloodstream of an individual irrespective of his/her underlying immunocompromised state. Another major lesson from our patient is the necessity to always send at least two sets of blood cultures in clinically suspected sepsis patients.8 More number of blood culture bottles increases the sensitivity and yield of microorganisms causing sepsis.9 It is a common practice to brush off Gram positive bacilli as a contaminant from one bottle of blood since Bacillus is one of the most common contaminants.10 In our patient, the organism was isolated from two (aerobic) bottles out of four (two aerobic and two anaerobic) bottles of blood sent for culture. In order to establish the pathogen, it is convenient to collect adequate quantity of blood and convincing evidence would be isolation of the organism of questionable significance from more than one blood culture bottles. In previously published reports, vancomycin, a glycopeptide group of antibiotic has been used in treating patients with B. clausii sepsis. Our patient was treated with another glycopeptide, teicoplanin and successful elimination of the bacterium from blood was achieved. Since interpretative guidelines for teicoplanin are not mentioned in CLSI, the same could not be interpreted from patient’s isolate. However, following successful treatment in our patient, it can be postulated that teicoplanin is an effective alternative in treating sepsis due to B. clausii. A major challenge in treating B. clausii sepsis is the limited therapeutic options. This is due to the fact that B. clausii is an organism known to carry multiple drug resistant genes.11 This could be a reason for treatment failure in patients from previously published reports. Initiation of appropriate antibiotic as well as adequate dosage was another perk in our case which resulted in better patient outcome. Therefore, a thorough knowledge on resistance pattern is mandatory while dealing infections with exotic/unusual organisms. Good bacteria can turn bad, good bacteria can carry drug resistant genes, good bacteria can be recalcitrant to therapy and require high end antibiotic therapy. The bacterial strains used as probiotics can become virulent and establish themselves as pathogens. The mechanism of virulence is still questionable especially in normal individuals, thereby warranting thorough research on the same.
Conclusion
Bacillus clausii may be safe as a probiotic but its use in immunocompromised and chronically ill patients is definitely questionable. This therapeutic dilemma is due to its probable ability to transmigrate from the gut into the blood stream and cause sepsis as experienced in our patient. There are no previous reports of B. clausii sepsis among adults with no known underlying chronic disease or immunocompromising condition. This case report can thus be taken as a wakeup call for making judicious use of this probiotic even in normal individuals. We conclude by stating that use of probiotics containing Bacillus clausii spores in critically ill patients cannot always be termed as beneficial; rather its use be considered with a word of caution.